Phase 1 Single Subcutaneous Dose Study of MLN1202

NCT02426021 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business decision; No Safety or Efficacy Concerns

Conditions

Healthy Japanese and Caucasian Male Adults

Interventions

DRUG: MLN1202
DRUG: MLN1202 Placebo

Sponsor

Takeda